Reference SummaryDeMayo FJ, Am J Physiol 1991 Aug;261(2 Pt 1):L70-6
Title |
Expression of SV40 T antigen under control of rabbit uteroglobin promoter in transgenic mice. | ||||||||||||||||
Authors |
DeMayo FJ; Finegold MJ; Hansen TN; Stanley LA; Smith B; Bullock DW | ||||||||||||||||
Journal |
Am J Physiol | ||||||||||||||||
Volume |
261 | ||||||||||||||||
Issue |
2 Pt 1 | ||||||||||||||||
Year |
1991 | ||||||||||||||||
Pages |
L70-6 | ||||||||||||||||
Abstract |
The rabbit uteroglobin gene is expressed in the lungs and reproductive tracts of male and female rabbits. To examine whether the promoter region of the uteroglobin gene could be used to target a heterologous gene to the lungs of transgenic mice, a fusion gene consisting of 3.3 kb of the 5'-flanking region of the rabbit uteroglobin gene and the large T antigen gene of the SV40 virus was constructed and microinjected into the pronuclei of one-cell mouse embryos. Eleven founder transgenic mice (5 female and 6 male) were generated. Seven of these mice developed bronchioalveolar neoplasms. Four of the founder males also developed primitive undifferentiated urogenital tract tumors. One founder female and one female offspring of a founder male developed glandular paraovarian tumors. Northern analysis revealed that the predominant site of expression of the transgene was the lung. Immunohistochemical staining showed T antigen predominantly in epithelial cells lining the bronchioles, the submucosal glands of the trachea, and the neoplasms. There appeared to be a high level of mosaicism for the transgene in the founder mice, with poor transmission of the transgene to subsequent generations. This suggests that, under the control of the uteroglobin promoter, the T antigen gene may be lethal to the fetus. | ||||||||||||||||
Links |
J:70786 – MGI References 1872417 – National Library of Medicine/PubMed |
||||||||||||||||
Strain Notes
|
Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
---|---|---|---|---|---|
FVB-Tg(UGB-TAg)2033Fjd | Larynx hyperplasia | Larynx |
100 |
||
FVB-Tg(UGB-TAg)6247Fjd | Lung - Club cell hyperplasia | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)2013Fjd | Lung - Club cell tumor | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)2025Fjd | Lung - Club cell tumor | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)2033Fjd | Lung - Club cell tumor | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)5554Fjd | Lung - Club cell tumor | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)5784Fjd | Lung - Club cell tumor | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)6247Fjd | Lung - Club cell tumor | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)6430Fjd | Lung - Club cell tumor | Lung - Club cell |
100 |
||
FVB-Tg(UGB-TAg)6430Fjd | Lung - Club cell tumor | Lung - Club cell |
0 |
||
FVB | Lung tumor | Lung |
0 |
||
FVB-Tg(UGB-TAg)1651Fjd | Ovary tumor | Ovary |
100 |
||
FVB-Tg(UGB-TAg)5554Fjd | Ovary tumor | Ovary |
100 |
||
FVB-Tg(UGB-TAg)2033Fjd | Thyroid gland carcinoma | Thyroid gland |
100 |
||
FVB-Tg(UGB-TAg)2025Fjd | (Unspecified organ) tumor | Pelvis |
100 |
||
FVB-Tg(UGB-TAg)2031Fjd | (Unspecified organ) tumor | (Unspecified organ) |
0 |
||
FVB-Tg(UGB-TAg)2033Fjd | (Unspecified organ) tumor | Pelvis |
100 |
||
FVB-Tg(UGB-TAg)2228Fjd | (Unspecified organ) tumor | (Unspecified organ) |
0 |
||
FVB-Tg(UGB-TAg)5554Fjd | (Unspecified organ) tumor | Pelvis |
100 |
||
FVB-Tg(UGB-TAg)5786Fjd | (Unspecified organ) tumor | (Unspecified organ) |
0 |
||
FVB-Tg(UGB-TAg)6430Fjd | (Unspecified organ) tumor | Pelvis |
100 |
||
FVB-Tg(UGB-TAg)6430Fjd | (Unspecified organ) tumor | Pelvis |
0 |